ArrowArtboardCreated with Sketch.Title ChevronCrossEye IconIcon FacebookIcon LinkedinShapeCreated with Sketch.Icon Mail ContactPath LayerIcon MailMenu BurgerIcon Opinion QuotePositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Takeda Pharmaceutical Co., Ltd.

  • 4,357.00 JPY
  • +64.00
  • +1.49%
  • Japan
    Nov 16, 2018
  • Ticker
    TKS(4502)
  • Prev. close
    4,293
  • Market cap (JPY)
    3,411.65B
  • Market cap (USD)
    30,087.79M
  • Shares
    794.70M

Business Summary

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2018 JPYUSD
Revenue1,770.53B15,974.84M
Gross Profit1,148.86B10,365.80M
Operating income195,320M1,762.30M
Income before tax217,205M1,959.76M
Net income186,886M1,686.20M
EBITDA377,447M3,405.56M
Diluted EPS237.552.14
Dividends Per Share1801.62
Total Assets4,106.46B38,612.71M
Total liabilities2,089.05B19,643.19M
Total equity1,997.42B18,781.60M
Operating cash flow379,600M3,424.99M
Currency in JPYCurrency in USD

Historical Data

 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 1,691.68B 1,777.82B 1,807.37B 1,732.05B 1,770.53B
Gross Profit 1,060.98B 1,134.39B 1,161.84B 1,017.65B 1,148.86B
Operating income 145,604M 195,804M 175,770M 86,972M 195,320M
Income before tax 158,851M -145,437M 120,542M 143,346M 217,205M
Net income 106,658M -145,775M 80,166M 114,940M 186,886M
EBITDA 332,856M 387,391M 353,275M 258,398M 377,447M
Diluted EPS 134.95 -185.37 101.71 146.25 237.55
Dividends Per Share 180 180 180 180 180
Total Assets 4,569.14B 4,296.19B 3,824.08B 4,346.79B 4,106.46B
Total liabilities 2,028.50B 2,090.01B 1,812.88B 2,397.82B 2,089.05B
Total equity 2,470.73B 2,137.04B 1,948.69B 1,894.26B 1,997.42B
Operating cash flow 148,335M 183,441M 26,552M 260,067M 379,600M
 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 16,887.88M 16,183.14M 15,050.91M 15,994.93M 15,974.84M
Gross Profit 10,591.64M 10,326.11M 9,675.22M 9,397.74M 10,365.80M
Operating income 1,453.54M 1,782.36M 1,463.72M 803.15M 1,762.30M
Income before tax 1,585.79M -1,323.88M 1,003.81M 1,323.75M 1,959.76M
Net income 1,064.75M -1,326.95M 667.58M 1,061.43M 1,686.20M
EBITDA 3,322.86M 3,526.33M 2,941.89M 2,386.22M 3,405.56M
Diluted EPS 1.34 -1.68 0.84 1.35 2.14
Dividends Per Share 1.79 1.63 1.49 1.66 1.62
Total Assets 44,367.08M 35,823.98M 34,023.62M 39,009.18M 38,612.71M
Total liabilities 19,697.13M 17,427.69M 16,129.56M 21,518.70M 19,643.19M
Total equity 23,991.25M 17,819.86M 17,337.88M 16,999.56M 18,781.60M
Operating cash flow 1,480.81M 1,669.82M 221.11M 2,401.63M 3,424.99M

Valuation Measures

Mar 2018
PER21.65
ROA4.42%
ROE9.60%
Operating margin11.03%
Profit margin10.55%

Key executives

  • President, CEO & Representative Director: Christophe Weber
  • Chief Financial Officer: Costa Saroukos
  • Director, Chief Medical & Scientific Officer: Andrew S. Plump
  • Executive Officer & Global General Counsel: Yoshihiro Nakagawa
  • Global Human Resources Officer & Executive Officer: David Osborne

Shareholders

  • Nippon Life Insurance Co. (5.4%)
  • The Vanguard Group, Inc. (3.8%)
  • Nomura Asset Management Co., Ltd. (3.2%)
  • Causeway Capital Management LLC (2.5%)
  • Mondrian Investment Partners Ltd. (2.3%)
  • Takeda Science Foundation (2.2%)
  • Wellington Management Co. LLP (1.9%)
  • Glenview Capital Management LLC (1.8%)
  • BlackRock Fund Advisors (1.7%)
  • State Street Global Advisors Ltd. (1.6%)

Contact Details

Related Companies

  • Takeda Consumer Healthcare Co. Ltd.
  • Takeda Pharmaceutical Director Incentive Plan
  • Takeda Pharmaceutical Employee Incentive Plan
  • Oy Leiras Takeda Pharmaceuticals AB
  • Takeda Architectural Design Consulting (Shanghai) Co. Ltd.
  • Takeda Pharma AB
  • Takeda Development Center Americas, Inc.
  • Takeda Ukraine LLC
  • Takeda Pharmaceuticals Taiwan Ltd.
  • Takeda SRL
  • Takeda Hellas SA
  • Takeda Christiaens SCA/CVA
  • Takeda Belgium SCA/CVA
  • Takeda Vaccines Pte Ltd.
  • Takeda Pharmaceuticals (Asia Pacific) Pte Ltd.
  • Takeda Development Center Asia Pte Ltd.
  • Takeda Pharma Sp zoo
  • Takeda Mexico SA de CV
  • Takeda Kazakhstan LLP
  • Takeda Pharmaceuticals Korea Co., Ltd.
  • Takeda Farmaceutica Espana SA
  • Takeda Pharma Ltda.
  • Takeda Distribuidora Ltda.
  • Takeda Vaccines, Inc.
  • Takeda Pharma SA
  • Takeda Pharma Vertrieb GmbH & Co. KG
  • Takeda (China) Holdings Co. Ltd.
  • Takeda Pharmaceutical (China) Co. Ltd.
  • Takeda Pharmaceuticals LLC
  • Takeda Nederland BV

Competitors

  • Dr. Reddy's Laboratories Ltd.
  • Ipsen SA
  • Amgen Inc.
  • RedHill Biopharma Ltd.
  • Hypera S.A.
  • YungShin Global Holding Corp.
  • MorphoSys AG
  • Celgene Corporation
  • Assembly Biosciences, Inc.
  • Peptron. Inc.
  • Galapagos NV
  • Shire PLC
  • CymaBay Therapeutics, Inc.
  • Protagonist Therapeutics, Inc.
  • Ironwood Pharmaceuticals, Inc. Class A
  • Seattle Genetics, Inc.
  • Albireo Pharma, Inc.
  • Sierra Oncology, Inc.
  • Nektar Therapeutics
  • Miragen Therapeutics, Inc.
  • Adaptimmune Therapeutics PLC Sponsored ADR
  • arGEN-X SE
  • Karyopharm Therapeutics, Inc.
  • BeiGene, Ltd.
  • Synergy Pharmaceuticals, Inc.
  • Golden Biotechnology Corp.
  • Atara Biotherapeutics Inc
  • Blueprint Medicines Corp.
  • Deciphera Pharmaceuticals, Inc.
  • SillaJen, Inc.
Last Updated on 16 Nov, 2018

You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month

Subscribe to get unlimited access to all articles.

Get unlimited access
NAR site on phone, device, tablet

{{sentenceStarter}} {{numberReadArticles}} free article{{numberReadArticles-plural}} this month

Stay ahead with our exclusives on Asia; the most dynamic market in the world.

Benefit from in-depth journalism from trusted experts within Asia itself.

Try 3 months for $9

Offer ends September 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media